Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)

Clinical trial NCT05853575 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05853575
Sponsor: Mirati Therapeutics Inc.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Advanced Cancer Metastatic Cancer Malignant Neoplasm of Lung

Start date: 2024-02-01
Primary completion: 2026-10-30
Enrollment: 200

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.